Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Status:
Completed
Trial end date:
2019-06-14
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well ponatinib hydrochloride works in treating patients
with biliary cancer that has spread to other places in the body and that have alterations
(fusions) in a gene known as fibroblast growth factor receptor 2 (FGFR2). Ponatinib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.